Dyspepsia Drugs Market size was valued at USD 10.12 billion in 2024 and is likely to cross USD 18.16 billion by 2037, expanding at more than 4.6% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of dyspepsia drugs is estimated at USD 10.49 billion. The market is expanding due to the rising prevalence of gastroesophageal reflux disease. Around the world, gastroesophageal reflux sickness has become increasingly more generally known as ongoing indigestion prompting expanded interest for compelling dyspepsia therapy.
According to the report, GERD symptoms occur in about 33% of all people worldwide. The prevalence of GERD also varies between men and women, with men more likely to have complications and extraesophageal symptoms.
In addition to this, a factor that is believed to fuel the growth of the dyspepsia drugs market is the growing need for sophisticated pharmaceutical therapies. Pharmaceutical companies can anticipate a substantial increase in demand for dyspepsia drugs as the incidence of GERD continues to grow, which confirms the market's growth.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.6% |
|
Base Year Market Size (2024) |
USD 10.12 billion |
|
Forecast Year Market Size (2037) |
USD 18.16 billion |
|
Regional Scope |
|
Type (Antacids, Proton Pump Inhibitors)
In dyspepsia drugs market, antacids segment is poised to hold more than 57% share by 2037. The segment’s growth is driven by growing trend towards self-care. Heartburn and dyspepsia are prominent symptoms of periodic dyspepsia, which is a widespread condition worldwide. People who want to get relief from these symptoms quickly are driving the demand for antacids.
Due to their accessibility and over-the-counter availability, antacids are a common choice for individuals experiencing mild to moderate dyspeptic discomfort. Nearly 40% of people globally, according to a poll, occasionally experience dyspeptic symptoms. Many persons who experience occasional dyspeptic symptoms prefer to treat their symptoms on their own and use non-prescription options.
Because antacids are widely acquired without a prescription over-the-counter, they meet customers' needs for quick, convenient relief. Antacids' rapid onset of action is a significant advantage. For those seeking quick symptom alleviation from disorders associated with acid reflux, antacids offer a convenient solution.
End User (Hospitals, Retail Pharmacies, Online Pharmacies)
In dyspepsia drugs market, hospitals segment is estimated to hold more than 48% revenue share by 2037. Hospital-based therapies are required due to the increasing incidence of severe dyspeptic disorders, which include consequences such as gastrointestinal bleeding, perforated ulcers, and refractory dyspepsia.
Since these situations necessitate specialist medical treatment, the demand for sophisticated therapeutic approaches and extensive inpatient care is driving the rise of the hospital’s category. Serious consequences from complicated gastrointestinal diseases may need emergency medical intervention.
To manage these cases, which require pharmacological therapies, endoscopic procedures, and diagnostic tests, hospitalization becomes necessary. As medical personnel handle the complexity of severe dyspeptic illnesses in an inpatient setting, the hospital segment is growing.
Hospitals are the central locations for extensive diagnostic tests, such as gastroscopy, which are used to determine the underlying reasons for dyspepsia. Patients are drawn to hospital settings by the requirement for precise diagnosis and specialist interventions like therapeutic endoscopy and tissue biopsies. The dyspepsia drugs market is estimated to grow significantly in the segment due to the above-mentioned elements.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
End-users |
|
|
Age Group |
|
|
Treatment |
|
APAC Market Statistics
Dyspepsia Drugs Market in the Asia Pacific industry is predicted to hold largest revenue share of 35% by 2037. The market growth in the region is also expected on account of the high prevalence of H.pylori. Therefore, the increasing need for pharmacological therapy to treat H. pylori-associated dyspepsia, is influencing the market growth in the region.
Urbanization and changing eating patterns are two factors that are causing dyspepsia to become more common in the Asia-Pacific area. More spicy and high-fat food consumption is associated with gastrointestinal distress, necessitating the use of drugs called dyspepsia. The correlation between food choices and dyspepsia in the area is what drives the necessity for medications to alleviate the condition's symptoms. In this context, the Asia Pacific dyspepsia drugs market is expanding.
North America Market Analysis
The North America region will also encounter huge growth for the dyspepsia drugs market during the forecast period and will hold the second position owing to the increasing prevalence of GERD. For instance, every day, approximately 10-20% of Americans suffer GERD symptoms. Proton pump inhibitors (PPIs) and H2 blockers are two dyspepsia treatments that are required for the vast population with GERD, which is driving the market's rise.
The rising rate of dyspepsia in North America is attributed to lifestyle-related variables, such as obesity. The need for dyspepsia medications is fueled by obesity's association with increased incidence of GERD and other gastrointestinal problems. Lifestyle modifications might not be enough on their own, which would push people to look for pharmaceutical remedies and expand the dyspepsia drugs market.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?